DAC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
On the other hand, the number of Japanese tourists declined after the exemption took effect. In addition, citizens of these countries will be allowed to use the electronic visa, which had been in effect before the unilateral exemption. The reinstatement of the visa requirement for tourists from the aforementioned countries, which was originally to occur starting in October 2023, was initially postponed to January 2024 and then to April 2024. Officially, the government declared that the measure sought not to harm tourism during the high season. In reality, the postponement resulted from the inability of local consulates to deal with the new demand, making it impossible for thousands of American and Canadian tourists to obtain visas in time to travel to Brazil. In 2024, Brazil reached a historic record in the entry of foreign tourists, with more than 6.6 million international travelers in the country. In 2025, the Brazilian passport ranked 16th among the 20 most powerful in the world according to the American consultancy Henley & Partners, while the international Passport Index ranking placed it 11th. Between January and September 2025, Brazil reached a historic record of 7 million tourists for the first time. According to Marcelo Freixo, president of Embratur, the record is the result of the government's effort to "rebuild Brazil's image in the world as a destination of diversity and sustainability".
SR-16435 is a drug which acts as a potent partial agonist at both the μ-opioid receptor and nociceptin receptor. In animal studies it was found to be a potent analgesic, with results suggestive of reduced development of tolerance and increased activity against neuropathic pain compared to classic μ-selective agonists.
An eminent historian nominated by the Government of India who shall be Chairman of the Council Eighteen historians nominated by the Government of India; Representative of the University Grants Commission (UGC) Director General of the Archaeological Survey of India Director General of the National Archives of India Four persons to represent government who shall be nominated by the Government of India and which shall include one representative each of the Ministry of Education, the Department of Culture and the Ministry of Finance, and the Member Secretary, who is appointed by the Council of the ICHR on a deputation basis for a period of three years, with the approval of the Ministry of Human Resource Development, Government of India.
Sources: en.wikipedia.org
Signs of sickle cell disease usually begin in early childhood. The severity of symptoms can vary from person to person, as can the frequency of crisis events. Sickle cell disease may lead to various acute and chronic complications, several of which have a high mortality rate.
Adams (1935), Kafka scholar and professor at the University of California, Los Angeles Frederick Hartt (1935), Michelangelo expert, professor at University of Virginia, member of the Monuments, Fine Arts, and Archives program Herbert Aptheker (1936), Marxist historian and political activist Maurice Matloff (1936), chief historian of the United States Army 1970–1981 John Alexander Moore (1936), professor of zoology at University of California, Riverside Joseph Greenberg (1936), prominent linguist known for work in linguistic typology and genetic classification of languages Carl E. Schorske (1936), cultural historian and winner of the 1981 Pulitzer Prize for History Quentin Anderson (1937), cultural historian and literary critic Charles Frankel (1937), political philosopher, assistant secretary of state for educational and cultural affairs Herbert Hyman (1939), sociologist and expert on opinion polling Herbert E. Klarman (1939), professor of the economics of healthcare at New York University Barry Ulanov (1939), English professor and scholar of jazz and religion Robert J.
=== Total contact casting === Total contact casting (TCC) is a specially designed cast designed to take the weight of the foot (off-loading) in patients with DFUs. Reducing pressure on the wound by taking the weight of the foot has proven to be very effective in DFU treatment. DFUs are a major factor leading to lower leg amputations among the diabetic population in the US, with 85% of amputations in diabetics being preceded by a DFU. Furthermore, the 5 year post-amputation mortality rate among diabetics is estimated at 45% for those with neuropathic DFUs. TCC has been used for off-loading DFUs in the US since the mid-1960s and is regarded by many practitioners as the "reference standard" for off-loading the bottom surface (sole) of the foot. TCC helps patients maintain their quality of life. By encasing the patient's complete foot — including the toes and lower leg — in a specialist cast to redistribute weight and pressure from the foot to the lower leg during everyday movements, patients can remain mobile. TCC redistributes pressure, protects the wound, letting damaged tissue regenerate and heal. TCC also keeps the ankle from rotating during walking, which helps prevent shearing and twisting forces that can further damage the wound. Effective offloading is a key treatment modality for DFUs, particularly those where there is damage to the nerves in the feet (peripheral neuropathy). Along with infection management and vascular assessment, TCC is a vital aspect to effectively managing DFUs. TCC is the most effective and reliable method for off-loading DFUs.
Sources: en.wikipedia.org
The first Zaxbys was established in Statesboro, Georgia, in March 1990, near the Georgia Southern University campus, by childhood friends Zach McLeroy and Tony Townley; the first restaurant was known as "Zax" before becoming Zaxby's. The company's first restaurant outside of Georgia was opened in September 1994 in Bowling Green, Kentucky. In 2013, they opened locations in Utah, the first expansion outside of the southeastern United States. In 2022, Zaxbys appointed Bernard Acoca as its first non-founder CEO. Zach McLeroy remained as chairman, while Tony Townley exited the company following its acquisition by Goldman Sachs in November 2020. In 2024, Zaxbys announced expansion plans for 2025, including a store in Cambridge, Maryland, the first location in the state. More locations are slated to open along the Eastern Shore of Maryland in the coming years. As of 2025, Zaxbys had more than 970 locations throughout the U.S.
=== Other vaccines === In May 2024, Moderna's mResvia, an mRNA respiratory syncytial virus vaccine, was authorized for medical use in the United States. The company's mCombriax, a combined messenger RNA vaccine for protection against influenza and COVID‑19 was authorized for marketing in the European Union in February 2026. Their influenza vaccine, mFlusiva (mRNA-1010), was approved for medical use in the United States in August 2026 for people over the age of 50.
== Similar forms == Arenobufagin is a derivative of the so-called bufadienolides, where it also has a steroid structure. A characteristic of bufadienolides is that they all contain two double bonds in the lactone ring.
The wide-spread interest in the very remarkable specimen of the giant squid, now lying on the beach a few miles below the city, is mainly due to its enormous size. It is believed to be the largest specimen ever found. Its great size and immense weight have thus far prevented its being moved for a more careful examination. A dozen men with blocks and tackle not being able even to turn it over. Another effort will be made with more extensive apparatus by which it is hoped to drag it from the pit in which it now lies and placing it higher up on the beach so that a careful and thorough examination in the interest of science can be made and the exact species determined. Professor Verrill of Yale and Profs. True and Dale [Dall] of the Smithsonian are in constant correspondence with Dr. DeWitt Webb, President of the St. Augustine Scientific, Literary and Historical Society, in regard to it. Several photographs have been taken of it, but owing to its position, these have not been satisfactory. Mrs. John L. Wilson believes it to belong to an extinct species. Its hide is three and a half inches thick and its head is covered by a hood that prevents examination. Apparently it is a mass of cartilage and may have been dead in the water many days before it washed ashore on Anastasia Island. In the February issue of the American Journal of Science, Verrill even gave the animal a scientific name, Octopus giganteus (Verrill, 1897). He also added:
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.